ZA922899B - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
ZA922899B
ZA922899B ZA922899A ZA922899A ZA922899B ZA 922899 B ZA922899 B ZA 922899B ZA 922899 A ZA922899 A ZA 922899A ZA 922899 A ZA922899 A ZA 922899A ZA 922899 B ZA922899 B ZA 922899B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
calcium deficiency
deficiency diseases
treating calcium
provides
Prior art date
Application number
ZA922899A
Other languages
English (en)
Inventor
Tudor Arvinte
Amelia Cudd
Judith Phillips
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA922899B publication Critical patent/ZA922899B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
ZA922899A 1991-04-23 1992-04-22 Pharmaceutical compositions ZA922899B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919108634A GB9108634D0 (en) 1991-04-23 1991-04-23 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA922899B true ZA922899B (en) 1993-10-22

Family

ID=10693744

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922899A ZA922899B (en) 1991-04-23 1992-04-22 Pharmaceutical compositions

Country Status (19)

Country Link
US (1) US5593962A (de)
EP (1) EP0510913B1 (de)
JP (1) JP3532580B2 (de)
KR (1) KR100245534B1 (de)
AT (1) ATE194775T1 (de)
AU (1) AU653395B2 (de)
CA (1) CA2066532C (de)
CY (1) CY2246B1 (de)
DE (1) DE69231263T2 (de)
DK (1) DK0510913T3 (de)
ES (1) ES2150418T3 (de)
GB (1) GB9108634D0 (de)
GR (1) GR3034414T3 (de)
IE (1) IE921278A1 (de)
IL (1) IL101622A (de)
MX (1) MX9201825A (de)
NZ (1) NZ242440A (de)
PT (1) PT510913E (de)
ZA (1) ZA922899B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
AU3556400A (en) 1999-03-17 2000-10-04 Novartis Ag Pharmaceutical compositions
EP1251867A4 (de) 2000-02-04 2004-12-08 Unigene Lab Inc Nasale calcitoninformulierungen
RS52966B (sr) * 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
JP2011516541A (ja) * 2008-04-07 2011-05-26 ナショナル インスティテュート オブ イミュノロジー 糖尿病および他の慢性疾患の治療に有用な組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions

Also Published As

Publication number Publication date
ATE194775T1 (de) 2000-08-15
GB9108634D0 (en) 1991-06-12
AU1506692A (en) 1992-10-29
US5593962A (en) 1997-01-14
EP0510913A2 (de) 1992-10-28
IL101622A0 (en) 1992-12-30
CA2066532A1 (en) 1992-10-24
MX9201825A (es) 1992-10-01
NZ242440A (en) 1993-10-26
EP0510913A3 (en) 1993-12-15
GR3034414T3 (en) 2000-12-29
DE69231263T2 (de) 2000-12-21
KR100245534B1 (ko) 2000-03-02
IL101622A (en) 1996-06-18
EP0510913B1 (de) 2000-07-19
CA2066532C (en) 2003-08-19
IE921278A1 (en) 1992-11-04
DK0510913T3 (da) 2000-10-16
JPH05139993A (ja) 1993-06-08
DE69231263D1 (de) 2000-08-24
PT510913E (pt) 2000-12-29
ES2150418T3 (es) 2000-12-01
JP3532580B2 (ja) 2004-05-31
CY2246B1 (en) 2003-07-04
AU653395B2 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
MX9204229A (es) Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
GR3035682T3 (en) Non-glycosylated fgf-4 and compositions containing the same.
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
IL87421A0 (en) Pharmaceutical compositions containing 5-amino(or substituted amino)-1,2,3-triazoles
SE9802937D0 (sv) Novel compounds
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ZA922899B (en) Pharmaceutical compositions
GB9516012D0 (en) Pharmaceutical composition
NZ222434A (en) Tissue factor protein lacking its naturally associated phospholipid
AP9200355A0 (en) "Therapeutic agent"
IL89392A0 (en) Compositions for the treatment of osteoporosis in humans comprising 24,25-dihydroxy-vitamin d3
IL108197A0 (en) Pharmaceutical composition for preventing or treating arterioscleriosis
PL345204A1 (en) Compounds with growth hormone releasing properties
ZA966953B (en) Pharmaceutical composition.
ZA928198B (en) Substituted azaspiranes for use in the treatment of hyperlipidemia
GB9217547D0 (en) Leather treatment compositions
IL96455A0 (en) Pharmaceutical compositions for the treatment of hsv
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
GB2262886B (en) N-channel calcium antagonists useful for treating bronchial diseases
PH31066A (en) Treatment composition.
GB2230444B (en) Therapeutic compositions.
ZA96446B (en) Use of 3,4-diphenyl chromans for the manufacture of pharmaceutical composition for the treatment or prophylaxis of obesity